These results of our work tangibly corroborate the intriguing interlayer interaction in in-plane isotropic/anisotropic heterostructures and are expected to shed light on designing balanced-performance multifunctional optoelectrical devices. On January 30, 2020, WHO declared COVID-19 a pandemic. https://www.selleckchem.com/products/vit-2763.html In this article we describe our experience at Richmond University Medical Center with Chembio serological IgM, IgG testing. In this prospective cohort study of patients and hospital employees, we utilized Chembio COVID-19 IgM/IgG serological testing in addition to Cepheid RT-PCR analysis. We evaluated the performance of Chembio serological test for IgM and IgG as an employee screening tool in a community hospital setting. The total number of currently asymptomatic employees screened was 1,866 from the Richmond University Medical Center. The non-exposed group included 1,253 (67.1%) employees with no significant clinical history and non-reactive IgM and IgG antibodies. The convalescent group included 255 (13.7%) of the employees with elevation of IgG only, 18 (1%) employees with past history of positive PCR and COVID-19 who currently have non-reactive IgM and IgG antibodies or demonstrate elevated IgG only, followed by 3 employees (< 1%) with no past clinical history who demonstrated reactive IgM and IgG antibodies and negative follow up by PCR. The reported 14.9% exposure/convalescent rate is lower than the reported 20% by the Department of Health and Governor Andrew Cuomo and may represent a better utilization of personal protective equipment, better hand washing techniques, and better disinfection procedures combined with strict social distancing. Chembio's performance is satisfactory; however, hospitals must design their own policies addressing who needs to be screened and who will interpret the results as well as constructing management algorithms for employees with no previous history and current double positive antibodies. Chembio's performance is satisfactory; however, hospitals must design their own policies addressing who needs to be screened and who will interpret the results as well as constructing management algorithms for employees with no previous history and current double positive antibodies. To investigate the clinical value of multi-index combined detection in the diagnosis of new coronavirus disease 2019 (COVID-19). A total of 63 laboratory confirmed patients treated in our hospital were selected as the COVID-19 group, including 28 severe patients and 35 non-severe patients. Another 50 healthy subjects undergoing physical examination simultaneously were selected as the healthy group. Here we performed a study on the laboratory characteristics and explored their efficacy for diagnosis of the disease. Compared with healthy people, the abnormal indicators of patients with COVID-19 are low levels of lymphocytes (LYM), red blood cells (RBC), hemoglobin (HGB), platelets (PLT), total protein (TP), and albumin (ALB), and high levels of monocytes (MON), aspartate aminotransferase (AST), gamma glutamyl transpeptidase (GGT), and C-reactive protein (CRP). The level of MON and CRP in severe patients were significantly increased compared with non-severe pneumonia patients, and indicators such as LYM an COVID-19 and predict the severity more effectively and accurately. To evaluate the diagnostic value of peripheral blood parameters including white blood cell (WBC), neutrophil, lymphocyte, monocyte, platelet, mean platelet volume (MPV), platelet distribution width (PDW), mean corpuscular volume (MCV), red cell distribution width (RDW), neutrophil-to-lymphocyte ratio (NLR), monocyte-to-lymphocyte (MLR), platelet-to-lymphocyte ratio (PLR) and platelet-to-neutrophil ratio (PNR) for neonatal pneumonia. Two hundred and six full-term neonates in our hospital from January 2018 to December 2019 were enrolled, including 73 pneumonic neonates and 133 health controls. Peripheral blood parameters were measured by an automatic blood cell analyzer. While C-reactive protein (CRP) and PCT concentrations were detected by electrochemical luminescence assay. Clinical signs, characteristic population, temperature, and chest radiograph findings were recorded. The receiver operating characteristic (ROC) curve was used to determine the cutoff values and analyze the diagnosis significances for neonatal pneumonia. This study showed that WBC, neutrophil, RDW, NLR, and MLR levels in the pneumonic group were higher than that of the control group, whereas lymphocyte, monocyte, platelet, and PNR levels were lower (p < 0.05). The ROC curve result showed that NLR and PNR owned higher AUC values than the rest of peripheral blood variables. At a cutoff value 2.581, NLR exhibited 63.01% sensitivity, 90.98% specificity, and 0.847 area under ROC curve (AUC). In addition, at a cutoff value 52.77, PNR showed 84.93% sensitivity, 78.95% specificity, and 0.856 AUC. This study clarifies that peripheral blood parameter of NLR and PNR have good applied value in diagnosis neonatal pneumonia with high sensitivity and specificity. This study clarifies that peripheral blood parameter of NLR and PNR have good applied value in diagnosis neonatal pneumonia with high sensitivity and specificity. Although increasing evidence has shown that long non-coding RNA BLACAT1 could be aberrantly expressed and used as a prognostic marker in various cancers, the results remain inconclusive. In this study, we sought to summarize the relationship between BLACAT1 (bladder cancer associated transcript 1) and relevant clinical outcomes. Eligible studies were retrieved from the online databases PubMed and Web of Science. A meta-analysis was performed using Stata 12.0 software. The Cancer Genome Atlas (TCGA) dataset was further used to verify the results. A total of sixteen studies were included to evaluate the association of BLACAT1 with overall survival or clinicopathological features by pooled hazard ratio (HR) or odds ratio (OR) in cancer. In the pooled analyses stratified by clinicopathological features, BLACAT1 expressions were closely correlated with lymph node metastasis (OR = 2.52, 95% CI 1.86 - 3.40, p = 0.000), histological differentiation (OR = 1.98, 95% CI 1.25 - 3.13, p = 0.004), and tumor stage (OR = 1.